1. Exposure to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the association with neurocognitive side effects: a meta-analysis and meta-regression. (25th November 2020) Authors: Hirsh-Raccah, B; Yanovsky, A; Rotshild, V; Danenberg, H; Eliaz, R; Matok, I Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗